The invention relates to a composition, and a medicament for preventing or stopping of metastases, in particular metastases originating from epithelia cancer, such as skin cancer, lung cancer, stomach cancer, brain cancer, breast cancer, colo-rectal cancer, prostate cancer, pancreas cancer, head/neck cancer, and esophagus cancer. It has been found that the present composition irreversibly converts cancer cells with metastatic potential into harmless cells with no metastatic potential.

The present invention relates to solid oral compositions with controlled release of active ingredients, comprising a core consisting of a monolithic matrix comprising at least one low-, medium- or high-viscosity hydroxypropyl methylcellulose, or a mixture thereof, a hydroxypropyl cellulose (HPC) and one or more superdisintegrant polymers, and an outer coating of said core consisting of a layer comprising hydroxypropyl methylcellulose and/or ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers.

The present invention relates to solid oral compositions with controlled release of active ingredients, comprising a core consisting of a monolithic matrix comprising at least one low-, medium- or high-viscosity hydroxypropyl methylcellulose, or a mixture thereof, a hydroxypropyl cellulose (HPC) and one or more superdisintegrant polymers, and an outer coating of said core consisting of a layer comprising hydroxypropyl methylcellulose and/or ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers.

A negatively charged glycosaminoglycan is provided for use as a medicament for the treatment of cancer. A combined administration of a negatively charged glycosaminoglycan is provided in which the glycosaminoglycan is characterised by the absence of the terminal pentasaccharide of Heparin, and an inhibitor of the MAPK/ERK pathway. A combined administration of a glycosaminoglycan and a MAPK/ERK pathway inhibitor is provided as a medicament for the treatment of cancer types that exhibit a resistance towards a single MAPK/ERK pathway inhibitor treatment.

A negatively charged glycosaminoglycan is provided for use as a medicament for the treatment of cancer. A combined administration of a negatively charged glycosaminoglycan is provided in which the glycosaminoglycan is characterised by the absence of the terminal pentasaccharide of Heparin, and an inhibitor of the MAPK/ERK pathway. A combined administration of a glycosaminoglycan and a MAPK/ERK pathway inhibitor is provided as a medicament for the treatment of cancer types that exhibit a resistance towards a single MAPK/ERK pathway inhibitor treatment.

A negatively charged glycosaminoglycan is provided for use as a medicament for the treatment of cancer. A combined administration of a negatively charged glycosaminoglycan is provided in which the glycosaminoglycan is characterised by the absence of the terminal pentasaccharide of Heparin, and an inhibitor of the MAPK/ERK pathway. A combined administration of a glycosaminoglycan and a MAPK/ERK pathway inhibitor is provided as a medicament for the treatment of cancer types that exhibit a resistance towards a single MAPK/ERK pathway inhibitor treatment.

The present invention relates to medical use of polysulfated polysaccharides and compositions thereof in the treatment of post-operative joint pain in a mammal. In particular, the invention relates to the use of the polysulfated polysaccharide, pentosan polysulfate, and compositions thereof in the treatment of aseptic persistent pain after joint arthroplasty in a mammal.

The present invention relates to medical use of polysulfated polysaccharides and compositions thereof in the treatment of post-operative joint pain in a mammal. In particular, the invention relates to the use of the polysulfated polysaccharide, pentosan polysulfate, and compositions thereof in the treatment of aseptic persistent pain after joint arthroplasty in a mammal.

The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance.

The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance.